Valuations of Early-Stage Companies and Disruptive Technologies: How to Value Life Science, Cybersecurity and ICT Start-ups, and their TechnologiesThis book will serve as a practical guide for entrepreneurs and investors/advisors in constructing and understanding valuations of startups in rapidly shifting industries, including the areas of drug development, medical devices, cyber security, and renewable energy. For large companies, valuation is based on forecasts of free cash flow; in technologically-driven industries, product pipelines can represent a large part of market capitalization. The situation is even more critical for small companies committed to a single idea: all of their value is linked to a single project. Any business transaction or internal proposal to begin or terminate an R&D project in which innovative projects are being valued or exchanged requires a realistic valuation of those projects. Moreover, different projects have very different dynamics. Pharmaceuticals have very large lead times and are dependent on patents as well as out-licensing agreements. In contrast, software develops very quickly, and IP is hard to value. This book will be a guide to building appropriate valuations for companies competing in rapidly shifting industries and offering products under new business models where little precedent exists, taking both financial and behavioral issues into consideration. |
Contents
2 | |
Overcoming Valuation Hurdles How to Conduct Valuations Under Unique Circumstances | 21 |
Behavioral Factors How Psychology Affects Bias in Valuations | 48 |
An Introduction to Valuations in RDIntensive Industries | 88 |
Actual Valuations | 119 |
Other editions - View all
Valuations of Early-Stage Companies and Disruptive Technologies: How to ... Tiran Rothman No preview available - 2020 |
Valuations of Early-Stage Companies and Disruptive Technologies: How to ... Tiran Rothman No preview available - 2021 |
Common terms and phrases
According active addition analysis application approval assessment assets assume attention balance become behavior bias biologics biosimilars calculated capital CAPM cash flow clinical Company Company B’s company’s Completed Condition considered corporate costs create customers decisions determine devices drug early-stage economic effect elements equity estimated evaluation examines example expected expenses factors firm’s firms forecast future global growth higher human income increase indicates individuals industries investment investors involved limited loss manufacturing method million network security offer operating patients period pharmaceutical Phase platform positive potential present projects received refers regulatory renewable energy reports represents result risk sector share similar solutions specific stage statement studies success Table testing tion treat treatment trials United users valuation wind